Curevac NV Form 4 insider transactions

BioNTech SE announced the successful satisfaction of the minimum condition for its exchange offer for CureVac N.V., with 81.74% of shares tendered.

BioNTech announced CureVac shareholders overwhelmingly approved its exchange offer, setting the stage for the acquisition's completion with a defined exchange ratio.

BioNTech's third-quarter revenue surged 22% driven by a significant out-licensing deal with Bristol-Myers Squibb, despite a decline in COVID-19 vaccine sales and a confirmed full-year net loss outlook.

BioNTech SE reports narrower net losses for the nine months ended September 30, 2025, driven by out-licensing revenue, while progressing its public exchange offer for CureVac N.V. shares.

BioNTech SE has initiated an exchange offer to acquire all outstanding shares of CureVac N.V., as detailed in its recent SEC filing.

BioNTech SE has commenced its public exchange offer to acquire all outstanding shares of CureVac N.V. for an implied aggregate equity value of approximately $1.25 billion, aiming to bolster its mRNA-based cancer immunotherapy pipeline.

BioNTech SE initiates an exchange offer to acquire all issued ordinary shares of CureVac N.V., aiming to expand its mRNA and oncology capabilities, while reporting significant net losses for recent periods and projecting a net loss for 2025.

BioNTech SE announces a tender offer to acquire all outstanding shares of CureVac N.V., aiming to expand its mRNA oncology capabilities and diversify its product pipeline.

BioNTech SE has reached comprehensive settlement arrangements with CureVac and GSK, resolving global patent litigation related to mRNA COVID-19 vaccines and securing key licenses, contingent on its acquisition of CureVac.

BioNTech SE has settled patent litigation with CureVac and GSK, securing a non-exclusive license for mRNA-based COVID-19 and influenza products, alongside its ongoing acquisition of CureVac.

BioNTech SE has announced a definitive agreement to acquire CureVac N.V. through a public exchange offer, leading to CureVac's delisting and full integration into BioNTech's operations.

BioNTech SE announced its definitive agreement to acquire all shares of CureVac N.V., aiming to strengthen its mRNA-based cancer immunotherapy development and accelerate innovative cancer treatments.

BioNTech SE has announced a definitive Purchase Agreement to acquire all shares of CureVac N.V., a strategic move aimed at strengthening its mRNA-based cancer immunotherapy programs and integrating CureVac's research and manufacturing site.

BioNTech SE announced its planned acquisition of CureVac N.V. through an exchange offer valued at approximately $1.25 billion, aiming to integrate CureVac's mRNA technologies and manufacturing capabilities.

BioNTech SE has filed pre-commencement communications with the SEC regarding its proposed acquisition of CureVac N.V. through an exchange offer, outlining the procedural steps and associated risks.

BioNTech SE announced a definitive agreement to acquire CureVac N.V. in an all-stock transaction valued at approximately $1.25 billion, aiming to significantly strengthen its mRNA-based cancer immunotherapy capabilities.